Novo Nordisk Walks a Tightrope: Oral Wegovy Approved as Pipeline Drug Shines, Yet Hack and Rival Pressure Loom
13.06.2026 - 12:54:24 | boerse-global.de
The Danish pharmaceutical giant closed the week at €38.03, a modest 2% gain that does little to mask a year-to-date slump of nearly 45%. Beneath that flat surface, Novo Nordisk has been navigating one of its most contradictory weeks in recent memory — a regulatory breakthrough, promising early-stage data, a competitive setback, and a cyber attack that exposed sensitive patient information.
On June 11, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral version of Wegovy, marking the first time a GLP-1 weight-loss drug has been cleared as a pill in Europe. The decision, based on the OASIS-4 trial that showed a 16.6% weight reduction over 64 weeks, opens a new front in the obesity market. The oral formulation already has approval in the United Arab Emirates, with further international rollouts expected in the second half of the year. In the UK alone, roughly 55,000 people are on waiting lists with private providers, underscoring the pent-up demand that the pill could unlock.
Yet the same week delivered a cybersecurity blow. On June 12, attackers breached Novo Nordisk’s internal IT systems, stealing pseudonymised patient data from clinical trials — including biomarkers, lifestyle factors, and subject IDs — along with personal contact details of physicians and nurses. The company insists operations remain unaffected and that direct patient identification is unlikely. But the GDPR implications and the erosion of trust among trial participants and recruiting physicians pose a structural risk to a company whose future hinges on clinical data.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the pipeline front, the picture is equally mixed. Phase?2 data for Zenagamtide (also known as Amycretin), presented at the ADA Scientific Sessions in New Orleans, were compelling. The first-in-class dual GLP-1/amylin receptor agonist hit its primary endpoint across all six subcutaneous doses tested in 262 adults with type?2 diabetes. At the highest dose of 40?mg, HbA1c dropped by 1.71?percentage points after 36 weeks, 89% of patients achieved a reading below 7%, and body weight fell by 14.6%. Side effects were predominantly gastrointestinal and mild to moderate. Novo Nordisk plans to launch a phase?3 programme in the second half of 2026.
By contrast, CagriSema — a fixed-dose combination of cagrilintide and semaglutide — produced less convincing results. In the REIMAGINE?1 study, HbA1c fell by 1.8?percentage points and weight by 13.8%. But a head-to-head with Eli Lilly’s Zepbound in the REDEFINE?4 trial showed CagriSema delivering a 23% weight reduction after 84 weeks against 25.5% for Zepbound. While the gap is not dramatic, it has raised questions about the drug’s competitive edge. Novo Nordisk submitted a US approval application for CagriSema in obesity in December?2025, with an FDA decision expected in the fourth quarter of 2026.
Meanwhile, the financial picture remains strained. Adjusted revenue fell 4% in the first quarter of 2026, though management nudged up the full?year guidance to a decline of 4% to 12% (from 5% to 13%). Lower US pricing under the Most?Favoured?Nations rule and the patent expiry of semaglutide in some markets continue to weigh. The buyback programme chugs along: between June?1 and 4 Novo Nordisk repurchased 870,000 B?shares, bringing the 2026 total to roughly 18.76?million shares.
From a technical standpoint, the stock is treading water. It sits about 4.5% above its 50?day moving average of €36.38, but remains more than 8% below the 200?day average of €41.43. The 2026 low of €30.25 in March may represent the floor, but a sustained recovery is not yet in sight. Catalysts later this year — the FDA ruling on CagriSema and the first international launches of oral Wegovy — could shift the narrative, but the accumulation of headwinds, from the data breach to pricing pressure, suggests the stock’s recalibration is far from complete.
Ad
Novo Nordisk Stock: New Analysis - 13 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
